» Articles » PMID: 28841151

CCR7 Sulfotyrosine Enhances CCL21 Binding

Abstract

Chemokines are secreted proteins that direct the migration of immune cells and are involved in numerous disease states. For example, CCL21 (CC chemokine ligand 21) and CCL19 (CC chemokine ligand 19) recruit antigen-presenting dendritic cells and naïve T-cells to the lymph nodes and are thought to play a role in lymph node metastasis of CCR7 (CC chemokine receptor 7)-expressing cancer cells. For many chemokine receptors, N-terminal posttranslational modifications, particularly the sulfation of tyrosine residues, increases the affinity for chemokine ligands and may contribute to receptor ligand bias. Chemokine sulfotyrosine (sY) binding sites are also potential targets for drug development. In light of the structural similarity between sulfotyrosine and phosphotyrosine (pY), the interactions of CCL21 with peptide fragments of CCR7 containing tyrosine, pY, or sY were compared using protein NMR (nuclear magnetic resonance) spectroscopy in this study. Various N-terminal CCR7 peptides maintain binding site specificity with Y8-, pY8-, or sY8-containing peptides binding near the α-helix, while Y17-, pY17-, and sY17-containing peptides bind near the N-loop and β3-stand of CCL21. All modified CCR7 peptides showed enhanced binding affinity to CCL21, with sY having the largest effect.

Citing Articles

Genetic Encoding of Phosphorylated Amino Acids into Proteins.

Allen M, Karplus P, Mehl R, Cooley R Chem Rev. 2024; 124(10):6592-6642.

PMID: 38691379 PMC: 11658404. DOI: 10.1021/acs.chemrev.4c00110.


NMR indicates the N-termini of PSGL1 and CCR7 bind competitively to the chemokine CCL21.

Witt R, Nickel K, Binns J, Gray A, Hintz A, Kofron N Biochem Biophys Rep. 2023; 35:101524.

PMID: 37554427 PMC: 10404610. DOI: 10.1016/j.bbrep.2023.101524.


Fragment-based drug discovery of small molecule ligands for the human chemokine CCL28.

Zhou A, Jensen D, Peterson F, Thomas M, Schlimgen R, Dwinell M SLAS Discov. 2023; 28(4):163-169.

PMID: 36841432 PMC: 10339762. DOI: 10.1016/j.slasd.2023.02.004.


A potential antibody repertoire diversification mechanism through tyrosine sulfation for biotherapeutics engineering and production.

Zhong X, DAntona A Front Immunol. 2022; 13:1072702.

PMID: 36569848 PMC: 9774471. DOI: 10.3389/fimmu.2022.1072702.


New Insights of CCR7 Signaling in Dendritic Cell Migration and Inflammatory Diseases.

Hong W, Yang B, He Q, Wang J, Weng Q Front Pharmacol. 2022; 13:841687.

PMID: 35281921 PMC: 8914285. DOI: 10.3389/fphar.2022.841687.


References
1.
Seibert C, Sanfiz A, Sakmar T, Veldkamp C . Preparation and Analysis of N-Terminal Chemokine Receptor Sulfopeptides Using Tyrosylprotein Sulfotransferase Enzymes. Methods Enzymol. 2016; 570:357-88. PMC: 4817839. DOI: 10.1016/bs.mie.2015.09.004. View

2.
Wiley H, Gonzalez E, MAKI W, Wu M, Hwang S . Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst. 2001; 93(21):1638-43. DOI: 10.1093/jnci/93.21.1638. View

3.
Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard N . Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell. 1999; 96(5):667-76. DOI: 10.1016/s0092-8674(00)80577-2. View

4.
Veldkamp C, Seibert C, Peterson F, Sakmar T, Volkman B . Recognition of a CXCR4 sulfotyrosine by the chemokine stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12). J Mol Biol. 2006; 359(5):1400-9. PMC: 2670582. DOI: 10.1016/j.jmb.2006.04.052. View

5.
Ludeman J, Stone M . The structural role of receptor tyrosine sulfation in chemokine recognition. Br J Pharmacol. 2013; 171(5):1167-79. PMC: 3952796. DOI: 10.1111/bph.12455. View